Screening
pharmacology (and ADME/toxicology) of novel compounds. Evidently, both single-cell and multicellular anal-
ysis have their advantages and disadvantages in drug development and in compound screening, especially when used to phenotypically assess com- pound pharmacology and where there is little a priori knowledge of the molecular target(s). Currently, techniques for both single-cell and mul- ticell assay screening are rapidly advancing, as are imaging and multifluidic approaches that are already impacting phenotypic assays. There are few, if any, studies directly comparing the two approaches, a deficit in the field that should be addressed given the growing establishment of cell and tissue biobanks from patient cell populations, and their subsequent use in compound screening and profiling.
DDW
References 1 Friese, A et al. The convergence of stem cell technologies and phenotypic drug discovery. Cell Chemical Biology. 2019 26:1050. 2 Gao, D, Jin, F, Zhou, M and Jiang, Y. Recent advances in single cell manipulation and biochemical analysis on microfluidics. Analyst 2019, 144:766-781. 3 Heath, JR, Ribas, A and Mischel, PS. Single-cell analysis tools for drug discovery and development, Nat. Rev. Drug Discov. 15 (2016) 204-216. 4 Hwang, B et al. Single-cell RNA sequencing technologies and bioinformatics pipelines. Experimental & Molecular Medicine Volume 50, 2018. 5 Luo, T et al. Microfluidic Single-Cell Manipulation and Analysis: Methods and Applications. Micromachines. February 2019. 6 Craig, F. Microfluidics – driving innovation and streamlining single cell analysis. Drug Discovery World. https://www.ddw-
online.com/enabling- technologies/p322392- microfluidics-driving- innovation-and-streamlining-
single-cell-analysis.html. 7 Kaushik, et al. 2018 Stem Cell 2018 36:1329. 8 Kota, S et al. A novel three- dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype. Oncogene. 2018 37:4372- 4384. 9Takahashi. 2019, Ann Rev Pharmacol. Toxiol., 559:447 10 Kondo and Inoue. Cells 2019 8:470.
Dr Richard M. Eglen is an independent Board member, advisor and consultant, having recently retired from Corning Life Sciences, where he was Vice-President and General Manager. Eglen has more than 40 years’ senior executive management experience in the life sciences industry, leading organisations in both drug discovery and technol- ogy development. He has authored more than 325 publications, book chapters and patents, and serves on several industry, academic advisory and journal editorial boards.
Drug Discovery World Fall 2019 41
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
